ReviewCurrent fungal infection reports2021
Investigational Agents for the Treatment of Resistant Yeasts and Molds.
Review in Current fungal infection reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- The urgent and challenging superbug fungus Candidozyma auris (formerly Candida auris): a comprehensive review.Antonie van Leeuwenhoek · 2026Review
- Drug Discovery and Repurposing forJournal of fungi (Basel, Switzerland) · 2025Review
- Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects.Acta pharmaceutica Sinica. B · 2025Review
- Hydrophobic Interactions of Modified Coconut Oil and Pluronic 127 Enable Stable Formation of Bioactive Hydrogel for Onychomycosis.Gels (Basel, Switzerland) · 2025Article
- Antifungal and Antibiofilm Activities of 2-Aminobenzoic Acid Derivatives Against a Clinical OcularAntibiotics (Basel, Switzerland) · 2025Article
- Coccidioidomycosis: a growing global concern.The Journal of antimicrobial chemotherapy · 2025Review
- The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.Current research in microbial sciences · 2025Review
- Sphaeropsidin A Loaded in Liposomes to Reduce Its Cytotoxicity and Preserve Antifungal Activity AgainstMolecules (Basel, Switzerland) · 2024Article
- Epidemiology of Invasive Candidiasis.Clinical epidemiology · 2024Review
- Ibrexafungerp: A narrative overview.Current research in microbial sciences · 2024Review
- Broad susceptibility ofmBio · 2023Article
- No Chance to Survive:Antibiotics (Basel, Switzerland) · 2023Article
- The Arylamidine T-2307 as a Novel Treatment for the Prevention and Eradication ofInternational journal of molecular sciences · 2022Article
- Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020).Antimicrobial agents and chemotherapy · 2022Article
- Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections.Journal of fungi (Basel, Switzerland) · 2022Review
- Structural and functional investigation of ABC transporter STE6-2p fromProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Invasive Candidiasis: Update and Current Challenges in the Management of This Mycosis in South America.Antibiotics (Basel, Switzerland) · 2022Review
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.Drugs · 2021Review
- Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches.Infection and drug resistance · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review summarizes the investigational antifungals in clinical development with the potential to address rising drug resistance patterns. The relevant pharmacodynamics, spectrum of activity, preclinical studies, and latest clinical trial data are described. RECENT
findingsAgricultural and medicinal antifungal use has been selected for inherently drug-resistant fungi and acquired resistance mechanisms. The rates of fungal infections and immunocompromised populations continue to grow as few new antifungals have hit the market. Several agents with the potential to address the emergence of multidrug-resistant (MDR) molds and yeasts are in clinical development. SUMMARY: Evolved formulations of echinocandins, polyenes, and triazoles offer less toxicity, convenient dosing, and greater potency, potentially expanding these classes' indications. Ibrexafungerp, olorofim, oteseconazole, and fosmanogepix possess novel mechanisms of actions with potent activity against MDR fungi. Successful clinical development is neither easy nor guaranteed; thus, perpetual efforts to discover new antifungals are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.